Showing results (1-10 of 167) with videos related to
Sort By:
Pageof 17
Journal of Experimental Neuroscience|December 22, 2018
Is the History Repeated? Can (2R,6R)-Hydroxynorketamine be Another Antidepressant?Shigeyuki Chaki, Jun-Ichi YamaguchiThe Journal of Pharmacology and Experimental Therapeutics|January 25, 2017
Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-KetamineKenichi Fukumoto, Hidetoh Toki, Michihiko Iijima, et al.CNS Drug Reviews|April 15, 2006
ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxietyShigeyuki Chaki, Jun-ichi Yamaguchi, Hisaharu Yamada, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 27, 2018
(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in miceJun-Ichi Yamaguchi, Hidetoh Toki, Youge Qu, et al.The International Journal of Neuropsychopharmacology|June 13, 2018
No Sex-Specific Differences in the Acute Antidepressant Actions of (R)-Ketamine in an Inflammation ModelLijia Chang, Hidetoh Toki, Youge Qu, et al.Current Neuropharmacology|February 24, 2017
Beyond Ketamine: New Approaches to the Development of Safer AntidepressantsShigeyuki ChakiTrends in Pharmacological Sciences|April 18, 2017
mGlu2/3 Receptor Antagonists as Novel AntidepressantsShigeyuki ChakiAdvances in Pharmacology (San Diego, Calif.)|August 6, 2019
mGlu2/3 receptor antagonistsShigeyuki ChakiAdvances in Pharmacology (San Diego, Calif.)|July 4, 2020
mGlu2/3 receptor as a novel target for rapid acting antidepressantsShigeyuki ChakiNihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology|September 28, 2012
[The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant]Shigeyuki ChakiPageof 17